Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICAFUNGIN IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Treatment of candidemia, acute disseminated candidiasis, Candida peritonitis and abscesses,Treatment of esophageal candidiasis,Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life is approximately 13-20 hours in adults; supports once-daily dosing. Half-life is prolonged in moderate-to-severe hepatic impairment (Child-Pugh B/C) but no dosage adjustment is required.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Micafungin is metabolized by arylsulfatase and catechol-O-methyltransferase (COMT) to the M1 metabolite, and further metabolized by CYP3A4 to M2; however, CYP3A4 plays a minor role. The drug is not a significant inhibitor or inducer of CYP enzymes.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily biliary/fecal (≈71% of administered dose recovered in feces as parent drug and metabolites); renal excretion accounts for ≈15% (urine: <1% as unchanged drug).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Highly protein-bound (≥99.8%), primarily to albumin; slight binding to α1-acid glycoprotein.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Volume of distribution at steady state (Vss) is approximately 0.2-0.3 L/kg in adults; indicates limited tissue distribution, primarily confined to plasma and interstitial fluid.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Only available as intravenous infusion; oral bioavailability is negligible (<0.1%) due to poor gastrointestinal absorption.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No dosage adjustment required for any degree of renal impairment.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
In moderate hepatic impairment (Child-Pugh B), reduce dose to 100 mg once daily; no data for severe impairment (Child-Pugh C). No adjustment for mild impairment.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
For invasive candidiasis: 2 mg/kg (max 100 mg) intravenously once daily for patients ≥40 kg; 2 mg/kg once daily for patients <40 kg. For esophageal candidiasis: 3 mg/kg (max 150 mg) once daily.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific dose adjustment; use standard adult dosing based on renal and hepatic function.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
There is no FDA black box warning for micafungin.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions,Hepatic effects: elevations in liver enzymes, bilirubin, and rare cases of hepatic necrosis or hepatitis,Renal effects: elevations in serum creatinine and BUN,Hematologic effects: hemolytic anemia, leukopenia, thrombocytopenia,Injection site reactions: phlebitis, thrombophlebitis,Photosensitivity and risk of skin malignancies in patients with prolonged exposure
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to micafungin or any component of the formulation
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No known food interactions. Grapefruit and grapefruit juice do not interact with micafungin.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Micafungin is classified as FDA Pregnancy Category C. In animal studies, embryotoxicity and skeletal abnormalities were observed at doses 0.04 times the human dose. No adequate human studies exist. First trimester: Theoretical risk based on animal data; use only if benefit justifies risk. Second/third trimester: Limited data; may be used if clearly needed due to lack of alternative therapy.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Unknown if micafungin is excreted in human milk. Due to high molecular weight (ca. 1292 Da) and high protein binding (>99%), excretion is likely minimal. M/P ratio not determined. Caution advised; consider alternative therapy or temporarily discontinue breastfeeding during infusion.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy-induced physiological changes (increased plasma volume, enhanced renal clearance) may alter pharmacokinetics. However, specific dose adjustment guidelines are unavailable. Standard adult dosing (100-200 mg/day for invasive candidiasis) is typically used; monitor clinical response and serum drug levels if available.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Micafungin is an echinocandin antifungal that inhibits beta-(1,3)-D-glucan synthase. Administer IV only; do not bolus. Monitor hepatic function due to risk of elevated transaminases. Caution in patients with moderate to severe hepatic impairment (Child-Pugh B/C). Use with caution in patients with hypersensitivity to other echinocandins. May increase sirolimus and nifedipine levels; monitor levels. No renal dose adjustment needed. Do not mix with other drugs in same infusion line.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication is given intravenously to treat serious fungal infections.,Report any signs of allergic reaction: rash, itching, difficulty breathing, swelling of face or throat.,Monitor for symptoms of liver problems: jaundice, dark urine, abdominal pain, unexplained fatigue.,Inform your doctor about all medications you take, including over-the-counter drugs and supplements.,You may have blood tests to monitor liver function during treatment.,Do not drive or operate heavy machinery if you experience dizziness or confusion.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Micafungin, an echinocandin antifungal, inhibits CYP3A4 and P-glycoprotein, thereby decreasing the hepatic and intestinal metabolism of Lercanidipine, a CYP3A4 substrate. This leads to increased plasma concentrations of Lercanidipine, potentially causing excessive vasodilation, hypotension, reflex tachycardia, and peripheral edema. In severe cases, this interaction may precipitate syncope, myocardial ischemia, or acute kidney injury due to hypoperfusion."
"Rifapentine, a potent inducer of hepatic CYP450 enzymes and drug transporters, paradoxically increases serum concentrations of micafungin, an echinocandin antifungal. This interaction is thought to occur via inhibition of micafungin's biliary excretion and possibly through competitive binding to plasma proteins, leading to reduced clearance and elevated trough levels. Clinically, this may increase the risk of micafungin-related hepatotoxicity and requires close monitoring of liver function and therapeutic drug monitoring if available."
"Micafungin, a potent inhibitor of CYP3A4 and a substrate of CYP3A4, may reduce the hepatic clearance of Perhexiline, a CYP3A4 substrate with a narrow therapeutic index. Co-administration can result in elevated serum concentrations of Perhexiline, increasing the risk of hepatotoxicity and peripheral neuropathy. This interaction is significant as it may lead to adverse outcomes including liver injury and neurological deficits."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICAFUNGIN IN SODIUM CHLORIDE 0.9% vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
MICAFUNGIN IN SODIUM CHLORIDE 0.9% is a Electrolyte that works by Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICAFUNGIN IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICAFUNGIN IN SODIUM CHLORIDE 0.9% is: 100 mg intravenously once daily for invasive candidiasis; 150 mg intravenously once daily for esophageal candidiasis.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICAFUNGIN IN SODIUM CHLORIDE 0.9% and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICAFUNGIN IN SODIUM CHLORIDE 0.9% is classified as Category A/B. Micafungin is classified as FDA Pregnancy Category C. In animal studies, embryotoxicity and skeletal abnormalities were observed at doses 0.04 times the human dose. No adequate hum. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.